Bayforest Capital’s Pfizer PFE Stock Holding History

Bayforest Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,005	Closed	-$72.8K	–	879
2025 Q2	$72.8K	Buy	3,005 +1,901	+172%	+$44.3K	0.03%	504
2025 Q1	$28K	Buy	+1,104	New	+$28.9K	0.01%	614

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bayforest Capital's PFE Position: Q3 2025 in Review

Bayforest Capital sold out of Pfizer (PFE) in Q3 2025, closing a stake of 3,005 shares — an estimated $72.8K sold.

Bayforest Capital first reported a position in PFE in Q1 2025 and held it in 2 quarters. The position peaked at $72.8K in Q2 2025. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

Bayforest Capital reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
Bayforest Capital sold 3,005 Pfizer shares in Q3 2025, an estimated $72.8K.
Bayforest Capital first reported a position in Pfizer in Q1 2025 and held it in 2 quarters.
Bayforest Capital's Pfizer position peaked at $72.8K in Q2 2025.
2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Bayforest Capital's 13F filing for Q3 2025, filed 24 Oct 2025.